|
Demographics
|
|
Gender (% Male)
|
75.6
|
52.6
|
0.15
|
|
BMI (Kg/m2)
|
27.0 [16.2–44.8]
|
27.7 [21.7–48.5]
|
0.32
|
|
FFMI (Kg/m2)
|
18.3 [8.8–24.0]
|
17.6 [11.7–27.0]
|
0.75
|
|
Exacerbations (1 year prior)
|
0.0 [0.0–1.0]
|
2.0 [0.0–4.0]
|
<0.0001
|
|
Patient reported outcomes
|
|
SGRQ total
|
41.1 (15.5)
|
50.0 [22.2–82.3]
|
0.001
|
|
SGRQ symptoms
|
54.6 (19.9)
|
61.0 (17.5)
|
0.24
|
|
SGRQ impact
|
26.3 [2.1–71.6]
|
42.4 [4.6–60.1]
|
0.05
|
|
SGRQ activity
|
59.3 [0.0–100.0]
|
78.1 [22.5–100.0]
|
0.003
|
|
CAT
|
15.5 [9.0–35.0]
|
20.0 [9.0–37.0]
|
0.018
|
|
CES-D
|
12.0 [0.0–33.0]
|
15.0 [0.0–31.0]
|
0.58
|
|
Functional capacity
|
|
6MWD (metres)
|
440.5 (125.7)
|
347.3 (123.4)
|
0.023
|
|
Lung function
|
|
Vital capacity %
|
99.2 (21.9)
|
93.6 (13.1)
|
0.40
|
|
Total lung capacity %
|
110.2 (17.0)
|
110.5 (23.5)
|
0.96
|
|
Residual volume %
|
132.0 (30.4)
|
150.0 (55.9)
|
0.16
|
|
Inspiratory capacity %
|
93.1 (21.8)
|
91.4 (20.9)
|
0.81
|
|
FRC %
|
125.6 (25.7)
|
132.5 (45.9)
|
0.52
|
|
DLCO %
|
56.5 [40.0–102.0]
|
61.5 [32.0–115.0]
|
0.87
|
|
KCO %
|
75.5 (80.1)
|
74.7 (85.0)
|
0.53
|
|
VA %
|
81.4 (13.1)
|
76.9 (14.2)
|
0.29
|
|
Post FEV1 %
|
68.2 (12.3)
|
57.3 (12.8)
|
0.002
|
|
Reversibility %
|
−4.4 [−53.8–+8.0]
|
−8.1 [17.3–+8.3]
|
0.25
|
|
Reversibility mls
|
20.0 [−170.0–580]
|
90 [−120–200]
|
0.90
|
|
Change in FEV1 from baseline
|
−80.0 [−420.0–+939.0]
|
−120.0 [−531.0–+180.0]
|
0.07
|
|
Bacteriology
|
|
Bacterial load (genome copies/ml)
|
2.36 × 106 [0–8.89 × 108]
|
10.3 × 107 [0–1.76 × 108]
|
0.25
|
|
Colonised (% >1 × 104 total PPM)
|
71.4
|
77.2
|
1.00
|
|
Systemic inflammation
|
|
CRP (mg/L)
|
3.0 [1.0–20.0]
|
5.0 [2.0–20.0]
|
0.017
|
|
WBC (109/L)
|
6.9 [3.6–13.5]
|
7.5 [4.8–11.8]
|
0.73
|
|
Eosinophils (109/L)
|
0.2 [0.1–0.6]
|
0.2 [0.0–0.4]
|
0.24
|
